Shattuck Labs will present at two investor conferences in December 2024, focusing on its novel cancer and autoimmune disease therapeutics.Quiver AI SummaryShattuck Labs, Inc., a biotechnology company focused...
October has seen a flurry of insider trading activity across multiple sectors, with key executives making significant stock purchases. New Fortress Energy’s (
– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in...
– Dose escalation ongoing in Phase 1 clinical trial of SL-172154 in platinum-resistant ovarian cancer; combination trial with liposomal doxorubicin on...
- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors - -...
AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the...
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shattuck Labs, Inc. (NASDAQ: STTK) on behalf of long-term stockholders following...
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK) and certain...